This Article Full Text Full Text (PDF) Correction (v67,p3492) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shai, A. Articles by Lambert, P. F. Search for Related Content PubMed PubMed Citation Articles by Shai, A. Articles by Lambert, P. F.

The Human Papillomavirus E6 Oncogene Dysregulates the Cell Cycle and Contributes to Cervical Carcinogenesis through Two Independent Activities

¹ McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin and ² Arbor Vita Corporation, Sunnyvale, California

Requests for reprints: Paul F. Lambert, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706. Phone: 608-262-8533; Fax: 608-262-2824; E-mail: lambert{at}oncology.wisc.edu.

Cervical cancer is a leading cause of death due to cancer among women worldwide. Using transgenic mice to dissect the contributions of the human papillomavirus (HPV) 16 E6 and E7 oncogenes in cervical cancer, E7 was identified previously to be the dominant oncogene. Specifically, when treated with exogenous estrogen for 6 months, E7 transgenic mice developed cancer throughout the reproductive tract, but E6 transgenic mice did not. E6 contributed to carcinogenesis of the reproductive tract, as E6/E7 double transgenic mice treated for 6 months with estrogen developed larger cancers than E7 transgenic mice. In the current study, we investigated whether the E6 oncogene alone could cooperate with estrogen to induce cervical cancer after an extended estrogen treatment period of 9 months. We found that the E6 oncogene synergizes with estrogen to induce cervical cancer after 9 months, indicating that E6 has a weaker but detectable oncogenic potential in the reproductive tract compared with the E7 oncogene. Using transgenic mice that express mutant forms of HPV16 E6, we determined that the interactions of E6 with cellular -helix and PDZ partners correlate with its ability to induce cervical carcinogenesis. In analyzing the tumors arising in E6 transgenic mice, we learned that E6 induces expression of the E2F-responsive genes, Mcm7 and cyclin E, in the absence of the E7 oncogene. E6 also prevented the expression of p16 in tumors of the reproductive tract through a mechanism mediated by the interaction of E6 with -helix partners. [Cancer Res 2007;67(4):1626–35]

This article has been cited by other articles:

				S.-H. Chung, K. Wiedmeyer, A. Shai, K. S. Korach, and P. F. Lambert Requirement for Estrogen Receptor {alpha} in a Mouse Model for Human Papillomavirus-Associated Cervical Cancer Cancer Res., December 1, 2008; 68(23): 9928 - 9934. [Abstract] [Full Text] [PDF]

				M. Narisawa-Saito, Y. Yoshimatsu, S.-i. Ohno, T. Yugawa, N. Egawa, M. Fujita, S. Hirohashi, and T. Kiyono An In vitro Multistep Carcinogenesis Model for Human Cervical Cancer Cancer Res., July 15, 2008; 68(14): 5699 - 5705. [Abstract] [Full Text] [PDF]

				A. Shai, H. C. Pitot, and P. F. Lambert p53 Loss Synergizes with Estrogen and Papillomaviral Oncogenes to Induce Cervical and Breast Cancers Cancer Res., April 15, 2008; 68(8): 2622 - 2631. [Abstract] [Full Text] [PDF]

				K. Strati and P. F. Lambert Role of Rb-Dependent and Rb-Independent Functions of Papillomavirus E7 Oncogene in Head and Neck Cancer Cancer Res., December 15, 2007; 67(24): 11585 - 11593. [Abstract] [Full Text] [PDF]

				Multiple Properties of E6 Contribute to Cervical Cancer Cancer Res., April 1, 2007; 67(7): 3492 - 3492. [Full Text] [PDF]